JAK2 and myeloproliferative disorder: To independently confirm these results in human MPN cell lines and using a different cytokine to activate JAK2 signaling, HEL cells, and SET-2 cells were treated with 4OH-TAM or vehicle and were subsequently stimulated with thrombopoietin, to drive MPL-JAK2-STAT5 signaling.